Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide-Reference-Cited by-同舟云学术

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide

Published:2018-10-17 Issue:1 Volume:94 Page:5-9
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Tefferi Ayalew¹^ORCID,Szuber Natasha¹,Vallapureddy Rangit R.¹,Begna Kebede H.¹^ORCID,Patnaik Mrinal M.¹^ORCID,Elliott Michelle A.¹^ORCID,Christopher Hook C.¹,Wolanskyj Alexandra P.¹,Hanson Curtis A.²,Ketterling Rhett P.³,Pardanani Animesh¹,Gangat Naseema¹^ORCID

Affiliation:

1. Divisions of Hematology; Mayo Clinic; Rochester Minnesota

2. Department of Hematopathology; Mayo Clinic; Rochester Minnesota

3. Departments of Internal and Laboratory Medicine, Laboratory Genetics and Genomics; Mayo Clinic; Rochester Minnesota

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25294/fullpdf

Reference21 articles.

1. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis;Tefferi;Blood,2014